(±)-cis-tert-butyl 1-[4-(hydroxymethyl)piperidin-3-ol-1-yl] carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (±)-cis-tert-butyl 1-[4-(hydroxymethyl)piperidin-3-ol-1-yl] carboxylate
• 英文别名: cis-Tert-butyl 3-hydroxy-4-(hydroxymethyl)piperidine-1-carboxylate；tert-butyl (3R,4S)-3-hydroxy-4-(hydroxymethyl)piperidine-1-carboxylate
• 化学式: C₁₁H₂₁NO₄
• 分子量: 231.292
• InChiKey: ULXATPSIGBJTPI-IUCAKERBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  70
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (±)-cis-tert-butyl 1-[4-(hydroxymethyl)piperidin-3-ol-1-yl] carboxylate 在 吡啶 、 盐酸 、 4-二甲氨基吡啶 、 potassium fluoride 、 sodium azide 、 palladium 10% on activated carbon 、 氢气 、 silver trifluoromethanesulfonate 、 氯化铵 、 三乙胺 、 N,N-二异丙基乙胺 、 4,7,13,16,21,24-六氧-1,10-二氮双环[8.8.8]二十六烷 作用下， 以 甲醇 、 2-甲基-2-丁醇 、 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， -50.0~90.0 ℃ 、120.0 kPa 条件下， 反应 173.75h， 生成 4-methylbenzyl 1-[4-(pyrimidin-2-yl)aminomethyl-1,2,5,6-tetrahydro-pyridin-1-yl]carboxylate
  参考文献：
  名称：

  Synthesis and in vitro characterization of trans- and cis-[18F]-4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]-3-fluoropiperidine-1-carboxylates as new potential PET radiotracer candidates for the NR2B subtype N-methyl-d-aspartate receptor

  摘要：

  Diastereoisomeric compounds [F-18]cis- and [F-18]trans-4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]-3-fluoro-piperidine-1-carboxylates were successfully synthesized as new subtype-selective PET radiotracers for imaging the NR2B subunit containing NMDA receptors. Rat brain section autoradiographies demonstrated a high specific binding in NR2B/NMDA receptor rich regions for both radioligands. The measured logD(7.4) values as well as B-max/K-d ratios indicated that both radiotracers possess the adequate properties required for PET radiotracers. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.04.011
• 作为产物：
  描述：

  N-苄基-3-氧代哌啶-4-羧酸乙酯盐酸盐 在 palladium on activated charcoal sodium tetrahydroborate 、 一水合肼 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 (±)-cis-tert-butyl 1-[4-(hydroxymethyl)piperidin-3-ol-1-yl] carboxylate
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of benzamide derivatives as selective 5-HT4 receptor agonists

  摘要：

  It is thought that selective 5-HT4 receptor agonists-such as 4-amino-5-chloro-2-metboxy-N-[1-(6-oxo-6-phenylhexyl)piperidin-4-ylmethyl]benzamide (2)-have the ability to enhance both upper and lower gastrointestinal motility without any significant adverse effects.Modification of 2 was performed. Variation of the piperidin-4-ylmethyl moiety of 2 led to a decrease in the binding affinity for the 5-HT4 receptor. Following conversion of the carbonyl group on the benzoyl part to a hydroxyl or sulfoxide group, the binding affinity for the 5-HT4 receptor was retained although the effect on defecation was reduced. Many of the 4-amino-5-chloro-2-methoxy-N-(piperidin-4-ylmethyl)benzamides that had a ether or sulfide moiety in the side-chain part at the 1-position of the piperidine exhibited high affinity for the 5-HT4 receptor.Among these, phenylthio 41c and benzylthio derivative 44 were selective 5-HT4 receptor agonists, and had a similar effect on defecation to compound 2. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.02.016

文献信息

• Radiolabelling of 1,4-disubstituted 3-[18F]fluoropiperidines and its application to new radiotracers for NR2B NMDA receptor visualization
  作者：Radouane Koudih、Gwénaëlle Gilbert、Martine Dhilly、Ahmed Abbas、Louisa Barré、Danièle Debruyne、Franck Sobrio

  DOI：10.1039/c2ob26378e

  日期：——

  In order to develop a novel and useful building block for the development of radiotracers for positron emission tomography (PET), we studied the radiolabelling of 1,4-disubstituted 3-[18F]fluoropiperidines. Indeed, 3-fluoropiperidine became a useful building block in medicinal chemistry for the pharmacomodulation of piperidine-containing compounds. The radiofluorination was studied on substituted piperidines with electron-donating and electron-withdrawing N-substituents. In the instance of electron-donating N-substituents such as benzyl or butyl, configuration retention and satisfactory fluoride-18 incorporation yields up to 80% were observed. In the case of electron-withdrawing N-substituents leading to carbamate or amide functions, the incorporation yields depend on the 4-susbtitutent (2 to 63%). The radiolabelling of this building block was applied to the automated radiosynthesis of NR2B NMDA receptor antagonists and effected by a commercially available radiochemistry module. The in vivo evaluation of three radiotracers demonstrated minimal brain uptakes incompatible with the imaging of NR2B NMDA receptors in the living brain. Nevertheless, moderate radiometabolism was observed and, in particular, no radiodefluorination was observed which demonstrates the stability of the 3-position of the fluorine-18 atom. In conclusion, the 1,4-disubstituted 3-[18F]fluoropiperidine moiety could be of value in the development of other radiotracers for PET even if the evaluation of the NR2B NMDA receptor antagonists failed to demonstrate satisfactory properties for PET imaging of this receptor.

  为了开发用于正电子发射断层扫描（PET）示踪剂的新颖且有用的构建模块，我们研究了1,4-二取代的3-[18F]氟哌啶的放射性标记。实际上，3-氟哌啶已成为药物化学中含哌啶化合物的药效调控的有用构建模块。我们在具有供电子和吸电子N-取代基的取代哌啶上研究了放射性氟化。对于具有供电子N-取代基（如苄基或丁基）的情况，观察到了构型保持和令人满意的氟-18掺入产率，高达80％。在导致形成氨基甲酸酯或酰胺功能的吸电子N-取代基的情况下，掺入产率取决于4-取代基（2至63％）。该构建模块的放射性标记被应用于NR2B NMDA受体拮抗剂的自动放射合成，并通过商用的放射化学模块实现。对三种放射性示踪剂的体内评估显示，其脑摄取量极低，与在活脑中成像NR2B NMDA受体不兼容。然而，观察到了中等程度的放射性代谢，特别是未观察到放射性去氟化，这表明氟-18原子的3位点的稳定性。总之，1,4-二取代的3-[18F]氟哌啶部分可能对开发其他PET示踪剂有价值，即使NR2B NMDA受体拮抗剂的评估未能显示出适用于该受体PET成像的令人满意的特性。
• [EN] PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS DE PHÉNYL-HÉTÉROARYLE ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：TRANSTECH PHARMA INC

  公开号：WO2011103091A1

  公开（公告）日：2011-08-25

  The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.

  本发明提供了式（I）的苯基-杂环芳基衍生物及其药学上可接受的盐。这些化合物在治疗RAGE介导的疾病，如阿尔茨海默病方面是有用的。本发明还涉及制备式（I）化合物及其药学上可接受的盐的方法，包括含有这些化合物的药物组合物，以及在治疗RAGE介导的疾病中使用这些化合物和/或药物组合物的用途。
• Selective Isomerization via Transient Thermodynamic Control: Dynamic Epimerization of <i>trans</i> to <i>cis</i> Diols
  作者：Christian J. Oswood、David W. C. MacMillan

  DOI：10.1021/jacs.1c11552

  日期：2022.1.12

  Traditional approaches to stereoselective synthesis require high levels of enantio- and diastereocontrol in every step that forms a new stereocenter. Here, we report an alternative approach, in which the stereochemistry of organic substrates is selectively edited without further structural modification, a strategy with the potential to allow new classes of late-stage stereochemical manipulation and

  传统的立体选择性合成方法需要在形成新立体中心的每一步中进行高水平的对映体和非对映体控制。在这里，我们报告了一种替代方法，其中有机底物的立体化学被选择性地编辑而无需进一步的结构修饰，这种策略有可能允许新类别的后期立体化学操作并提供稀有或有价值的立体化学构型。在这项工作中，我们描述了通过氢原子转移光催化和硼酸介导的瞬态热力学控制实现环状二醇的选择性差向异构化，选择性地从原本受欢迎的反式异构体生成不太稳定的顺式产物。一系列取代模式和环尺寸适合选择性异构化，包括立体化学复杂的多元醇，例如雌三醇，以及无环邻位二醇的顺式差向异构化。此外，该策略使得糖端基异构体能够发生不同的差向异构化，从而可以从α-或β-构型糖苷获得不同的糖异构体。
• PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF
  申请人：Gohimukkula Devi R.

  公开号：US20110230458A1

  公开（公告）日：2011-09-22

  The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.

  本发明提供了式（I）的苯基-杂环取代衍生物及其药学上可接受的盐。这些化合物在治疗RAGE介导的疾病，如阿尔茨海默病中是有用的。本发明还涉及制备式（I）化合物及其药学上可接受的盐的方法，包括这些化合物的制药组合物，以及在治疗RAGE介导的疾病时使用这些化合物和/或制药组合物。
• Phenyl-Heteroaryl Derivatives and Methods of Use Thereof
  申请人：TransTech Pharma, Inc.

  公开号：US20130197007A1

  公开（公告）日：2013-08-01

  The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.

  本发明提供了式（I）的苯基-杂环芳基衍生物及其药学上可接受的盐。这些化合物可用于治疗RAGE介导的疾病，如阿尔茨海默病。本发明还涉及制备式（I）的化合物及其药学上可接受的盐的方法，包括这种化合物的制药组合物，以及使用这种化合物和/或制药组合物治疗RAGE介导的疾病。